Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Multiple Cancer Types

Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.
Lung, Non Small Cell
II
Horn, Leora
NCT03625323
VICCTHO1930

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: